Vyne Therapeutics Reports Q1 2025 Financial Results: Revenues Increase to $0.2M with Significant Rise in R&D Expenses
I'm PortAI, I can summarize articles.
Vyne Therapeutics reported Q1 2025 financial results with revenues of $0.2 million, up from $0.1 million in Q1 2024. R&D expenses rose to $6.1 million, while general and administrative expenses decreased to $3.3 million. The company has $50.3 million in cash and expects to sustain operations into H2 2026. Key updates include a Phase 2b trial for vitiligo with results expected mid-2025, and a Phase 1b trial for psoriasis on clinical hold due to safety concerns, which VYNE is addressing with the FDA.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments